https://www.ncbi.nlm.nih.gov/pubmed/16043204 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103385/
And as I said, you can't know if the people who had mild infections did so because the virus was deficient or whether their immune response was good. It's not enough to have the antigen, you also need the right adjuvant to mount a response. The last thing you want is to have antibodies that recognize the virus, but do not activate the immune system.
https://en.wikipedia.org/wiki/Antibody-dependent_enhancement...
https://jvi.asm.org/content/94/5/e02015-19
https://www.researchgate.net/publication/340005309_Potential...
The fact that the live attenuated approach worked with polio doesn't mean that it'll work with coronavirus, and if we're not careful we could accidentally worsen the situation.
I agree that this is worthwhile area of pursuit, but one that will take a long time to bear fruit. Maybe you think that studying the variants in the wild will allow us to skip over some animal studies with the live attenuated virus, but I doubt they can be skipped.